Glaucoma Clinical Trial
Official title:
A Prospective Analysis of Nerve Fiber Layer and Macular Changes After Pars Plana Vitrectomy
Since the introduction of vitrectomy in 1971, this procedure has become the third most
frequently performed ophthalmic surgery. Approximately 225,000 vitrectomies are performed
annually in the United States and indications continue to expand. Known long-term
complications of vitrectomy are relatively few and include retinal detachment and cataract
formation. Although much has been written in the literature concerning acute rises in
intraocular pressure (IOP) in the immediate postoperative period, there is surprisingly
little information on long term IOP outcomes after vitrectomy. A recent report by Chang
given at the LXII (62) Edward Jackson Memorial Lecture hypothesized a causal relationship
between vitrectomy and open-angle glaucoma (OAG) via oxidative stress exacerbated by removal
of the crystalline lens. A second report by Luk and colleagues reported similar conclusions
in a modified cohort. Both studies, were retrospective in nature and did not perform
baseline evaluations to exclude pre-existing glaucoma. Furthermore neither study accounted
for natural history. Finally, our analysis has not reproduced similar results.
The primary purpose of this study is to analyze the full spectrum of optic nerve and macular
changes between vitrectomized study eyes and their non-vitrectomized fellow eyes to control
for natural history. Baseline evaluations will include examination by fellowship trained
retina and glaucoma specialists, fundus photography, autofluorescence, optical coherence
tomography (macula and optic nerve) and automated visual field testing. At 3 month then
annually for 5 years after vitrectomy surgery, the cohort will undergo similar evaluation.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 |